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ABSTRACT

Cystinuria is an autosomal recessive genetic disorder characterized by the
defect of a renal transporter involved in cystine reabsorption. When this
transporter is deficient, cystine cannot be broken down and reabsorbed by the
body and is excreted via urine in high concentrations. The high levels of cystine
present in the urine eventually lead to recurrent cystine urolithiasis due to its
inability to solubilize. Despite having various forms of treatments such as thiol
pharmaceutical therapies such as tiopronin and urine alkalinizing agents like
potassium citrate, only few patients with cystinuria are able to successfully
decrease cystine urine concentration. We observed the effects of tiopronin on its
ability to inhibit and prevent stone formation and found it to be only moderately
effective. In addition to observing tiopronin as a therapeutic, we also looked into
the effects of potassium citrate as a treatment. We found potassium citrate to
have a varying effects on both urinary pH and stone formation. Recently, our lab
had shown that the nutritional-supplement α lipoic acid was an effective inhibitor
of cystine stone formation. Here, we continued to further confirm the effects of α
lipoic acid as an inhibitor and preventer of stone growth. Due to the unknown
mechanism of α lipoic acid, we hypothesized α lipoic acid to be promoting
cystine reabsorption through the Nrf2 pathway. In our Slc3a1-/-; Nrf2-/- mouse
model, the mice treated with α lipoic acid still continued to have a reduced rate of
stone formation. These results suggested Nrf2 was not the pathway in which α
lipoic acid was inhibiting stone growth. In addition, we observed the effects of the
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combination of potassium citrate and α lipoic acid since potassium citrate is a
standard of care of cystinuric patients. Our results suggested there are no adverse
effects when the two drugs are administered together.
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HIGHLIGHTS
•

The commonly used thiol therapeutic for cystinuria patients, tiopronin
(TIO), was shown to significantly decrease the rate of stone growth in the
Slc3a1-/- mouse model. However, the therapeutic was observed not to be
an effective stone formation preventer.

•

Potassium citrate (KCIT), an alkalinizing agent and a therapeutic that is a
part of the standard of care for all cystinuric patients, had varying effects
on stone formation and did not successfully alkalinize urinary pH.

•

Zee et al. recently reported the thiol antioxidant, α lipoic acid, to be an
effective inhibitor of cystine stone growth and inhibition. Our results
further confirmed this finding.

•

Nrf2, a transcription factor that mediates antioxidant response element
genes, was the hypothesized pathway α lipoic acid worked through to
inhibit stone growth. However, results with the Slc3a1-/-; Nrf2-/- mouse
model indicate this was not the mechanism LA worked through to induce
cystine stone inhibition in the Slc3a1-/- mouse.

•

The administration of potassium citrate and α lipoic acid in conjunction
was shown to have no adverse or additive or synergistic effects on one
another
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THESIS OVERVIEW
-/-

Cystinuric, Slc3a1 ,
mouse model

Drug Administration

Tiopronin

Potassium Citrate

α Lipoic Acid

Scanning with the microcomputed tomography
scanner
* To track in vivo stone
growth

Scanning

Potassium Citrate + α
Lipoic Acid Combination
administered to mice

-/-

-/-

Slc3a1 ; Nrf2
mouse model
Scanning

α Lipoic Acid
administration
Fig. 1 – Thesis overview. Three therapeutics: tiopronin, potassium citrate, and α
lipoic acid were administered to the cystinuric, Slc3a1-/- mouse model. The mice
were scanned on a weekly basis in order to track in vivo stone growth. The
combination of potassium citrate and α lipoic acid were administered to observe
the effects of the two drugs may have on one another. A Slc3a1-/-; Nrf2-/- mouse
model was administered α lipoic acid to observe the role the Nrf2 pathway
played in α lipoic acid’s ability to induce stone rate inhibition.
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BACKGROUND

Kidney Stone Disease is an Increasing Public Health Problem

Over the last 25 years, the prevalence of kidney stone formation has risen
in the U.S. and affects approximately 9% of adult American regardless of sex or
ethnicity (Arumuham & Bycroft, 2016; Scales, Smith, Hanley, & Saigal, 2012).
This rise has been speculated to be caused by change of active lifestyles to
sedentary ones and diet. Risk factors of stone formation generally include
obesity, diabetes, and certain metabolic syndromes such as gout. Stone formers
are at risk for hypertension, chronic kidney disease, and end-stage renal disease
(Khan et al., 2016). Although males have traditionally had higher incidences of
stone cases, recently females have been observed to have increased prevalence of
stone formation. The possible reason behind this rise in stone incidences in
females is the increasing obesity rates amongst both males and females
(Arumuham & Bycroft, 2016; Khan et al., 2016). There are five types of kidney
stones. Calcium oxalate is the most common stone type making up 80% of cases
meanwhile other forms of stones such as calcium phosphate, uric acid, struvite,
and cystine are respectively 5%, 9%, 8%, and 1% of stone incidences.
Idiopathic hypercalciuria patients make up 50% of calcium stone formers.
This is a medical condition in which there is an increased excretion of calcium
present in the body despite the lack of any diseases that could play a role in these
elevated levels. There are certain systemic diseases such as primary
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hyperparathyroidism and renal tubular acidosis that contributes to abnormal levels
of calcium present in the blood. These conditions can lead or cause the patient to
be at risk for calcium stone formation, but the majority of calcium based stone
formers are idiopathic hypercalciuria patients (Coe, Worcester, & Evan, 2016;
Khan et al., 2016; Worcester & Coe, 2008). Generally, patients with
hypercalciuria excrete approximately over 300 mg of calcium per day
(Lewandowski & Rodgers, 2004; Worcester & Coe, 2008). Normal patients
excrete 100-250 mg of calcium per day depending on the diet of the patient.
These increased levels of excretion can cause calcium based stones to arise.
Although calcium oxalate stones accounts for 80% of stone formers, calcium
phosphate stone incidences are generally also a small component of calcium
oxalate stone formation and the incidences are accounted in only 5% of kidney
stone forming patients.
Most uric acid stone formers either have gout or have a high protein diet
paired up with low fluid intake and makes up 9% of stone formers. There is a
high output of uric acid in these patients and this is either caused by the over
production of endogenous uric acid, which occurs in medical conditions such as
gout when uric acid cannot be properly metabolized, or there is a high dietary
intake of purine-rich foods (Arumuham & Bycroft, 2016). The high levels of uric
acid in the urine are insoluble in the concomitant acidic urine (pH level ≤ 5.5) that
these patients excrete. Due to this insolubility, uric acid stone formation can
arise.
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Struvite stones, on the other hand, are observed in only 8% of stone
formation cases and are potentiated by the bacterial infection of the Proteus or
Klebsiella or Providencia species that hydrolyzes urea to ammonium (Goel &
Wasserstein, 2012; Khan et al., 2016). The presence of ammonium raises the
urine pH from neutral to alkaline values. The precipitation of struvite occurs in
urine with these alkalinized conditions. Struvite stone formation can grow at a
rapid rate into large stones.

Cystinuria is an Inherited Kidney Stone Disease

Cystine based stones are the least prevalent form of stones and make up
only 1% of stone incidences. This type of stone case is usually the result of
cystinuria, which is a genetically inherited kidney stone disease, caused by
mutations in either or both SLC3A1 and SLC7A9 genes. These mutations
specifically impair the heterodimeric cystine/dibasic amino acid transporters in
epithelial proximal tubular cells of kidney nephrons (Mattoo & Goldfarb, 2008)
(Fig. 2A). These impaired transporters lead to the oversaturation of cystine in the
urine due to the lack of cystine reabsorption (Fig. 2B). Cystine is not soluble at
the physiological pH of urine and this is the cause of cystine urolithiasis in
patients with this disorder (Claes & Jackson, 2012).
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A

Proximal Tubular Lumen

Proximal Epithelial Cell

Blood
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B

Urine

Proximal Tubular Lumen

Proximal Epithelial Cell

Fig. 2 – Cystine reabsorption and the cystine transporter in normal patients and
cystinuric patients. The cystine transporter is a heterodimer of two subunits
encoded by the genes SLC3A1 and SLC7A9 and is expressed on proximal
epithelial cells. (A) In a normal patient, cystine is shuttled across the cystine
transporter and is broken down into two cysteines. The cyteines are reabsorbed
back into the body via the blood. (B) In cystinuric patients, the cystine
transporter is defected due to a mutation in either the SLC3A1 or SLC7A9 genes.
Thus, cystine cannot be broken down and is excreted via urine therefore there are
elevated levels of cystine present in the urine of cystinuric patients.
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Patients with cystinuria typically form their first kidney stone in the first
two decades of their lives and continue to have recurrent stone formation,
affecting their quality of life (Lee, Sahota, Ward, & Goldfarb, 2015; Varda et al.,
2016). Due to the high rate of cystine stone formation, patients are required to
have surgical interventions along with their oral therapeutics. Extracorporeal
shock wave lithotripsy (SWL) is a minimally invasive way to surgically remove
kidney stones by using high-energy acoustic waves to travel through the body to
fragment kidney stones into smaller pieces that will be able to pass through the
urinary tract. This is the preferred method of stone removal for most of the stone
cases previously discussed. However, SWL isn’t always the standard of stone
removal for cystine based stones. Although SWL can be an effective treatment
for cystine based stones, the composition of these types of stones are generally
resistant to the acoustic waves and are not easily fragmented. Thus, multiple SWL
treatments are necessary in order to fully fragment cystine stones (Claes &
Jackson, 2012; Varda et al., 2016). The gold standard of care for cystine stone
removal is percutaneous nephrolithotomy (PCNL), in which an endoscope is
percutaneously directed through the skin, muscle, and fat into the kidney for stone
removal and lithotripsy.

Treatment Options for Cystinuria are Limited

Patients with cystinuria excrete 300-400mg/L of cystine per day when
normal patients only excrete 30 mg/L of cystine on a daily basis (Claes &
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Jackson, 2012). In order to decrease this urine cystine concentration, patients are
recommended to drink 3 to 4 L of water/day. With this method, a large
consumption of fluid is necessary around the clock in order to keep the urine
cystine concentration diluted. However, many patients find it difficult to maintain
this method of treatment.
In the 1960s, Dent et al. observed cystine solubility to be pH dependent
and this proposed another way to target cystine urine concentration other than
increasing fluid intake. Urinary pH at 7.5 or above increases cystine solubility
(Goel & Wasserstein, 2012). Thus, urinary alkalinizing agents such as potassium
citrate, sodium citrate, and sodium bicarbonate are another form of treatment for
cystinurics. Potassium citrate (KCIT) is the first line of alkalinizing agent that is
often prescribed for patients and is also part of the standard of care for all kidney
stone patients. For cystinuria, KCIT is the preferred form of treatment as
compared to sodium citrate due to sodium’s ability to increase cystine excretion in
the urine. Although KCIT is a commonly used form of treatment for cystinuria
and other stone models, there is currently no knowledge on this treatment’s effect
on stone growth. It is important to establish an understanding since KCIT is a
widely used therapeutic for many kidney stone models.
Another method of increasing cystine solubility would be the use of
pharmacological cystine-binding thiol medications. D-penicillamine and
tiopronin (TIO) are two commonly used thiol drugs. The mechanism of how
these drugs work is that they reduce the disulfide bond of cystine and the drug
itself binds to one of the cysteine to make a drug-cystine complex. This complex
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is presumably 50 times more soluble in urine than cystine on its own (Dolin,
Asplin, Flagel, Grasso, & Goldfarb, 2005; Joly et al., 1999; Mattoo & Goldfarb,
2008). However, side effects of the thiol medications range from change in taste
perception, rashes, fever, and proteinuria (Claes & Jackson, 2012; Halperin,
Thier, & Rosenberg, 1981; Mattoo & Goldfarb, 2008). About 50% of patients
experience side effects and long term therapy may lead to vitamin B6 deficiency,
especially in those that are prescribed D-penicillamine. Thus, vitamin B6
supplements may also be prescribed in combination with the previously discussed
treatments for patients that are using that particular thiol drug. (Biyani &
Cartledge, 2006). Due to the adverse effects of D-penicillamine, TIO is the
preferred form of treatment in the United States due to its lessened side effects
and is more well-tolerated in patients (Claes & Jackson, 2012; Halperin et al.,
1981; Joly et al., 1999; Mattoo & Goldfarb, 2008). Regardless of these lessened
side effects of TIO, this drug can still have significant adverse effects on patients
and this can lead to the discontinuation of usage.
The goal of these limited amounts of therapeutics available for patients
mostly targets the oversaturation of cystine present in the urine to control or
inhibit stone formation. It is clinically successful when the cystine urine
concentration is less than 300mg/L, but only 15% of patients successfully achieve
lower cystine concentration in their urine due to the inefficiency of these
treatments (Mattoo & Goldfarb, 2008). Thus, there is a need to find other forms
of therapeutics.
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α Lipoic Acid as a Cystine Stone Inhibitor in the Mouse

α lipoic acid (LA) is commonly known as a thiol antioxidant of the
organosulfur compounds family that was discovered as an effective stone
inhibitor by our lab (Zee et al., 2017). As a therapeutic, LA was an effective
inhibitor and preventer of cystine stone growth compared to control groups that
were not administered the treatment in the Slc3a1-/- mouse model. Here, we
repeated previous experiments and saw similar results of LA’s ability to be an
effective stone inhibitor and preventer.
On the other hand, as an antioxidant, LA play a role in the antioxidant
response element (ARE) pathway against oxidative stress and various studies
have shown the organosulfur compounds family had shown to upregulate Nrf2
activation (Cui et al., 2012; Lii et al., 2010). Nrf2 is a transcription factor
regulating ARE-mediated genes. We hypothesized the Nrf2 pathway to be the
mechanism in which LA was working through in order to induce stone inhibition
and prevention by increasing Nrf2 nuclear translocation and cellular cystine
utilization in order to inhibit cystine stone growth (Han et al., 1997; Suh et al.,
2004).
Thus, one of the aims of our study focused on determining whether LA
was working through the Nrf2 pathway and observe the effects of TIO and KCIT
as a therapeutic for inhibiting stone growth and accumulation. In our study, we
used the Slc3a1-/- mouse model which exhibit many symptoms similar to its
human cystinuric counter partner and develop cystine urolithiasis. The micro-
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computerized tomography scanner (µCT) was utilized to track stone growth and
stone volume accumulated in our mouse model.
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METHODS AND MATERIALS

Mouse Model
All procedures and protocols were approved by the Institutional Animal Care and
Use Committee of the Buck Institute for Research on Aging. The mouse model
used was the Slc3a1-/- mouse with an A129 and C57Bl/J6 mixed background.
This model mimics all the symptoms human cystinuric patients present with the
oversaturation of cystine in urine and the formation of cystine stones (Ercolani et
al., 2010). Stone formation generally began around 2-3 months old. Only male
mice were experimented on. Female mice do not generally form stones and are
excluded from this study. Mice were kept in 12 hour light and 12 hour dark cycle
at 24C and had free access to food. An average number of 4 to 6 males are used
for each treatment group.

Drug Treatments
A solution of potassium citrate tribasic monohydrate (Sigma Aldrich, St. Louis,
MO) was mixed, changed, and weighed on a weekly basis to ensure the efficiency
of the drug and measure whether or not the mice were drinking the solutions. The
different dosages of 0.5%, 2%, and 4% KCIT solution were decided on previous
KCIT studies on rat and other mouse models of other kidney stone diseases
(Cebotaru et al., 2005; Krieger et al., 2015). The two other dosages, 1% and 1.5%
KCIT, were decided later in the study as two possible effective dosages due to
side effects of the 2% and 4% KCIT dosages. Mice were fed chow supplemented
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with 0.25% LA or 0.5% LA or 1% tiopronin (Envigo, Huntingdon, United
Kingdom). The control mice received normal water and chow. All mice involved
in experiments were randomized prior their placements in treatment groups to
avoid bias.

Urine Collection
Fresh urine was collected every 2 to 3 days. Mice were placed on cardboards
covered with plastic wrap. Any collectable amounts of urine (20+ µL) present on
the plastic wrap were collected immediately into Eppendorf tubes.

pH Reading
The Jenco 6230 pH meter (Jenco, San Diego, CA) was used to ensure pH
difference between the samples soon after the urine collections.

Micro-Computed Tomography (µCT)
The µCT scanner (SkyScan 1176, Bruker, Belgium) is a noninvasive method used
for to detect and to track the rate of stone growth. All mice received the general
anesthesia of 2 to 3% isoflourane before and during the scans and were placed in
a supine position. The scanner was set at these following settings: Resolution =
standard, image pixel size = 1000 x 668, averaging frames = 2, filter = AL 0.5
mm, X-ray voltage = 50 kV, anode current = 500 µA, rotation = 0.7, and exposure
time 4 minutes. Scans were performed weekly to detect, track, and measure the
rate of stone growth.
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Scan Analysis
Scans were reconstructed as cross-sectional three dimensional (3D) images with
the use of the software, NRecon (NRecon v1.6.9.8, Bruker-MircoCT, Belgium).
The dynamic range on this program was set to -0.002 to 0.08 to minimize the
background noise and ensure the consistency between the individual mouse scans.
The reconstructed 3D images were then exported to the image analysis software,
CT Analysis (CTAn v1.14, Bruker-MicroCT, Belgium). A threshold between 70
to 120 was chosen to obtain better contrast between the bladder wall and stones.
We used the circular region of interests to focus specifically on the bladder region
of these 3D images to detect and calculate the measurements of the amount of
stones present on a weekly basis.

Statistical Analysis
Littermate mice were randomly assigned to a treatment or control group for each
experiment. Means and standard errors were calculated in each treatment and
control group. Two-sided Student’s t-tests were used to determine statistical
significance between groups.
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RESULTS

Cystinuria is a genetic disorder that causes the lack of cystine reuptake.
The two genes that play a role in this disorder is SLC3A1 or SLC7A9. When
either of these genes is mutated, the cystine transporters expressed on the
proximal epithelial cells are defected. This deficiency leads to the lack of cystine
reabsorption by the body and cystine is excreted in elevated levels through urine
instead. The presence of excessive cystine in the urine presents a problem due to
cystine’s lack of solubility in the bodily fluid. Current medical therapeutics such
as tiopronin or D-penicillamine target cystine solubility, but is often an inefficient
preventative strategy, leaving patients with limited therapeutic options. Thus, we
observed tiopronin’s effect on stone formation since it is the preferred form of
thiol treatment in the United States due to its lessened adverse effects on patients
(Matoo & Goldfarb, 2008). The Slc3a1-/- mouse model we utilized in our
experiments were administered TIO at 2-3 months of age after they have already
started to form stones in order to observe TIO’s inhibitory effects on cysteine
stone growth (Fig. 3A). The results suggest there was a significant decrease on
the rate of stone growth when we compare the TIO treated group to the control
group.

In order to observe TIO as a preventative measure, the drug was

administered to younger mice around 1-2 months of age that had not yet formed
stones or had very little stone accumulation present in their bladders (Fig. 3B).
Our results indicate that although TIO was able to significantly decrease the rate
of stone growth, this therapeutic was not an effective inhibitor of stone formation.
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Fig. 3 –TIO effects on stones as an intervening and preventative treatment on
stone growth. (A) 2-3 month Slc3a1-/- male old mice were administered normal
(CONT) (n=8) chow and 1% TIO supplemented chow (n=9. Rates of stone
accumulation were expressed as means ± SEM. (B) 1-2 month old male mice
were administered CONT chow (n=9) and TIO supplemented food (n=9) and stone
volume accumulated was tracked for 3 months. Stone volumes were expressed as
means ± SEM.

In addition to observing tiopronin and its capabilities, KCIT’s possible
ability to inhibit stone formation was also looked into as well. Urinary pH is
known to affect the solubility of cystine, thus urine alkalinizing agents such as
KCIT is a commonly used mean of alkalinizing urinary pH as a standard of care
for cystinuria patients. Although KCIT is commonly used for patients, there is
19

very little known about this alkalinizing agent and its capabilities in inhibiting the
rate of stone formation. In our study, we want to use the highest effective dosage
to look at the effects of KCIT on stone formation.
0.5%, 2.0%, and 4% KCIT solutions were administered to mice. Within
the first week after the initial administration of the KCIT solution, the groups
ingesting both the 2.0% and 4.0% KCIT solution were observed to have
undergone either tremendous amounts of stress and were euthanized or were
found dead. We immediately stopped the administration of the two highest
dosages and began the administration of 1% and 1.5% KCIT solutions instead and
with careful observations. Urine was collected on a 2-3 day basis and pH was
measured by a pH meter. We discovered the 1.5% KCIT group eventually
developed complications similar to the 2% KCIT and 4% KCIT groups, thus we
discontinued the usage of it immediately. This action left 1% KCIT as our final
and highest dosage.
We looked into the effects of KCIT on stone growth with a range dosages
consisting of 0.25% KCIT, 0.5% KCIT, and 1% KCIT (Fig. 4A). Of the three
various dosages we administered, 0.5% KCIT was the most efficient at inhibiting
stone growth. Meanwhile the 0.25% KCIT and 1% KCIT had minimal to no
inhibitory effect on the rate of stone growth. In addition to tracking these
dosages’ effects on stone growth, we also kept track on their effects on weight
(Fig. 4B). All weights of all the groups were similar and within a normal range.
In addition, the effect of KCIT on urinary pH was also observed (Fig.4C). Our
results indicated that we were not successful in alkalinizing the urinary pH of our
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mice. There were no statistical significance between the urinary pH levels of the
untreated and treated mice.
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6.5
6.0
5.5
5.0
CONT

0.5% KCIT
Dosages

1% KCIT

Fig. 4 – Effect of varying dosages of KCIT on urinary stone formation,
weight, and urinary pH on Slc3a1-/- mice. (A) 2-3 month old male Slc3a1-/mice were administered three dosages ranging from 0.25% KCIT (n=5),
0.5% KCIT (n=5), 1% KCIT (n=4), and CONT water (n=5) for over a
month; a total of 6 µCT scans were conducted. Rates of stone growth are
expressed as mean ± SEM. (B) Weights of mice in the duration of the drug
treatments. Weights are expressed as mean ± SEM. (C) 2 month old male
Slc3a1-/- mice were administered normal water, 0.5% potassium citrate
(KCIT), or 1% KCIT solution for 2 months. Urine samples were collected
on a 3-4 day basis. pH of urine samples was measured by a pH meter. The
pH meter readings are expressed as mean ± SEM (n=4 per condition).

We recently reported the thiol antioxidant, LA, to be a successful inhibitor
and preventer of cystine stone formation in the Slc3a1-/- mouse mice (Zee et al,
2017). Here, we further confirm LA as an effective treatment of cystine stone
formation and prevention. In order to observe the effects of LA as an inhibitory
22

drug, we administered the drug to mice around 2 to 3 months of age and tracked
their rate of stone growth for 35 days (Fig. 5A). The group on LA treatment had a
significantly lower rate of stone growth when compared to the control group.
These results suggested that LA was a strong inhibiting treatment. In addition to
observing LA as an inhibiting stone growth treatment, we also observed this
treatment’s capabilities as a preventative treatment. We administered LA to
young mice that have not yet started to form stones or haven’t accumulated much
yet (Fig. 5B). Our results indicate LA to be an effective stone preventer of stone
formation.
Since LA’s mechanism of inhibiting stone formation is unknown, there are
possibilities of it acting as a urine alkalinizing agent such as KCIT. Thus, urine
from LA treated mice was collected to observe the possible alkalinizing effects
LA may have on urinary pH (Fig. 5C). The results suggest that LA did not
alkalinize the urinary pH of the mice during the administration of this drug. The
possible mechanism in which LA may be working through in order to inhibit
stone formation and prevention was not through alkalinizing urine. In addition,
we also kept track of the weights of the mice in the duration of the LA
administration to ensure the mice’s weights were within a normal range and our
results suggest that they were (Fig. 5D).
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Fig. 5 – LA as a treatment of cystine based stones. (A) 2-3 month old mice
were administered CONT food (n=8) and 0.5% LA supplemented chow (n=5)
for over one month; a total of a total of 7 µCT scans were conducted. Results
are expressed as means ± SEM. (B) CONT food (n=9) and LA supplemented
food (n=9) was given to mice 1-2 month old mice and stone accumulation was
tracked for 6 months. Results are expressed as mean ± SEM. (C) Urine
samples were collected on a 3-4 day basis and pH values were measured via pH
meter. Readings are expressed as mean ± SEM (n=5 per condition). (D)
Weights of mice in the duration of the drug treatment. Weights are expressed
as mean ± SEM (n=5 per condition). Two-tailed Student’s tests were used to
determine statistical significance.
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The mechanism in which LA worked through in order to inhibit stone
growth was unknown to us. As a known target of LA, the Nrf2 pathway was
hypothesized to be the mechanism that LA worked through to inhibit stone
growth. Nrf2 is an oxidative stress induced pathway that directly transcribes
antioxidant and detoxifying enzymes for cellular defense (Suh et al, 2004; Shi et
al, 2016; Shay et a, 2009). There are various studies that have shown
organosulfur compounds to increase upregulation of Nrf2 activation (Cui et al.,
2012; Lii et al., 2010). In the Slc3a1-/-; Nrf2+/+ mouse model, our results indicate
LA was able to successfully inhibit stone growth as we had previously see when
compared to the control group (Fig. 6A). We knocked out Nrf2 in our Slc3a1-/mice to create a double knockout mouse model in order to observe the possible
role the Nrf2 pathway had in LA’s ability to inhibit stone growth (Fig. 6B). The
results indicate that LA was still successful in inhibiting the rate of stone growth
despite the knockout of Nrf2 in the Slc3a1-/- mouse. These results suggest that
Nrf2 was not the mechanism in which LA worked through in order to inhibit
stone growth.
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Fig 6 – Nrf2 knockdown had no effect on LA’s ability to inhibit stone growth.
(A) 2 month old Slc3a1-/-; Nrf2+/+ mice on LA treatment for 2 months; a total
of a total of 11 µCT scans were conducted. Rate of stone growth are expressed
as means ± SEM (n= 4 per condition). (B) 2 month old Slc3a1-/-; Nrf2-/- mice
on LA treatment for 2 months. Rate of stone growth are expressed as means ±
SEM (n= 7 per condition). Two-tailed Student’s tests were used to determine
statistical significance.
Since urine alkalinizing agents are commonly used as a standard of care
for patients (Goel and Wasserstein, 2012), we therefore addressed whether the
usage of KCIT combined with LA would have an antagonistic, additive, or
synergistic effects on stone inhibition. A low dosage of LA was selected to pair
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up with a high dosage of KCIT. Our results showed that both the low dosage of
LA and high dosage of KCIT was able to independently decrease the rate of stone
growth (Fig. 7A). However, when we administer the two drugs in conjunction,
there seemed to be no antagonistic, additive, or synergistic effects of the two.
There are no significant differences between the different drug treatment
conditions. The effects of the drugs on the rate of stone growth was also mirrored
in the average amount of stone volume accumulated (Fig. 7B).
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Fig. 7 – Effect of KCIT and 0.25% LA on stone growth and accumulation.
(A) Average stone volume accumulation and (B) average rate of stone
growth was tracked by the µCT scanner for 3 months; a total of a total of 9
µCT scans were conducted. The data are presented as means ± SEM (n=6
per condition). Two-tailed Student’s tests were used to determine statistical
significance.
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DISCUSSIONS

Cystinuria is an autosomal recessive genetic disease that causes the lack of
cysteine reabsorption through the mutation of one of the genes, SLC3A1 or
SLC7A9. The mutation of either one of these two genes causes a defect in the
cystine transporter present in epithelial proximal tubular cells and leads to the lack
of cystine reabsorption. Since the body cannot reuptake cysteine due to the defect
of this transporter, cystine is excreted in excess via urine instead. The
oversaturation of cystine present in the urine eventually leads to cystine stone
formation. There are currently no known pharmacotherapies that have been
shown to successfully inhibit cystine stone formation although drugs such as Dpenicillamine and tiopronin are commonly used (Claes & Jackson, 2012; Mattoo
& Goldfarb, 2008). Aside from these thiol therapeutics, patients do not have
much treatment options aside from using the urine alkalinizing agent and
increasing fluid intake as methods to decrease aggressive cystine stone formation.
The conservative methods of treating cystinuria generally consist of the
combination of increased consumption of fluids and using alkalinizing agents to
target cystine urine concentration. These two methods are ineffective and the
addition of thiol pharmaceutical drugs such as D-penicillamine and TIO are
necessary to treat cystinuric patients. The use of D-penicillamine as a treatment
began in 1963 when the drug was observed to have a significant effect on cystine
solubility in patients of this genetic disease. Although the drug has been shown to
have tremendous side effects on patients that includes rashes, fever, proteinuria,
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and change in the perception of taste along with vitamin B6 deficiency since the
1960’s, patients are still prescribed this drug treatment (Claes & Jackson, 2012;
Crawhall, Scowen, & Watts, 1963; Halperin et al., 1981; Mattoo & Goldfarb,
2008).
Other forms of thiol therapies have been created since the introduction of
D-penicillamine with the hope that they will have the same effect on cystine
solubility with lessened side effects effects. Captopril and bucillamine are other
thiol pharmacotherapies available aside from the previously discussed Dpenicillamine and TIO. Unfortunately, there are few studies focused on these two
drugs and the effectiveness of them. Captopril was shown to decrease cystine
excretion in cystinuric patients, but the drug has been shown to have many
inconsistencies and was suggested to be used for patients that cannot control their
cystine stone formation with the use of D-penicillamine or tiopronin (Chow &
Streem, 1996; Cohen, Streem, & Hall, 1995; Halperin et al., 1981; Sloand & Izzo,
1987). Meanwhile, bucillamine had only been previously available to patients in
South Korea and Japan (Biyani & Cartledge, 2006). Thus, there a few available
clinical studies in the United States that observes the efficacy of bucillamine as a
new method of treatment.
TIO is currently the main choice of thiol treatment aside from Dpenicillamine in the U.S. due to both the drugs’ similar mechanism of action.
Due to this similar mechanism of action, TIO also have a similar side effect
profile as compared to D-penicillamine but this drug is better tolerated by
patients. Both of these thiol drugs had been shown to be effective in decreasing
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the rate of stone formation in patients, but many were still considered at a high
risk of stone reoccurrence (Chow & Streem, 1996). Our results mirrored what has
been seen in regards to TIO’s modest capability to intervene in the rate of growth
in our mice. Just as Chow and Streem had observed, our results indicate that TIO
was unable to successfully prevent stone formation unlike LA as a treatment.
Zee et al reported the oral administration of the thiol antioxidant, LA, as
an effective cystine stone inhibitor and preventer in the Slc3a1-/- mouse model as
compared to untreated Slc3a1-/- mice. In this study, LA was identified as an
effective inhibitor of stone growth through a drug screen consisting of various
compounds that have been shown to activate the ARE pathway to promote
glutathione synthesis and increase cellular cysteine uptake. Our results further
confirmed the report of LA’s abilities to act as an efficient inhibitor and preventer
of cystine stone formation. LA is a known thiol antioxidant that has been shown
to increase Nrf2, a transcription factor that mediates ARE mediated genes,
translocation and increase cellular cysteine utilization (Cui et al., 2012; Lii et al.,
2010). Due to these previously shown effects of LA, Nrf2 was the pathway we
hypothesized LA worked through in order to induce stone inhibition and
prevention in our mice. However, our results indicated that LA worked
independently of the Nrf2 pathway to inhibit stone formation in our Slc3a1-/-;
Nrf2-/- mice. The effects of LA treatment on the rate of stone growth in Slc3a1-/-;
Nrf2-/- mice were not significantly different compared to Slc3a1-/- mice.
Alkalinizing agents is a standard of care for all cystinuric patients in order
to increase urinary pH and increase cystine solubility (Dent, Friedman, Green, &
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Watson, 1965; Joly et al., 1999; Mattoo & Goldfarb, 2008). KCIT is the preferred
form of alkalinizing agents for patients over others forms. Citrate treatments such
as sodium citrate increase the cystine excretion in patients and this is not ideal in
the clinical setting. The increased excretion of cystine in the urine may have an
impact on the rate of stone reoccurrence in cystinuric patients thus sodium citrate
is a second line of treatment if necessary.

However, the usage of KCIT and

increasing liquid intake are generally not enough to tackle stone formation and
prevention alone. Thus, the addition of thiol drugs is necessary (Barbey et al.,
2000; Dolin et al., 2005). When we observe KCIT as a treatment without the
addition of increased fluid intake or thiol drugs, the treatment was shown to have
varying effects on stone formation and urinary pH. This may be due to various
factors. In regards to urinary pH, a factor as to why KCIT was not successful in
alkalinizing the urine of our mice may be due to KCIT’s varying effects on
urinary pH in the clinical setting and our results may be mirroring what is
commonly seen in the clinic (Asplin & Asplin, 2013; Barbey et al., 2000). Or,
another possibility is that KCIT may be working through another mean of action
that is independent of urinary pH such as through its metabolites in order to
increase cystine solubility and inhibit stone formation.
Some inconsistencies could be due to how KCIT was administered to our
mice since the method of drug administration plays a crucial role in any
experimental design (Turner, Brabb, Pekow, & Vasbinder, 2011). KCIT was
given to the mice in their drinking water instead of other methods such as gavage
or a KCIT supplemented diet to mirror clinical settings (Joly et al., 1999; Mattoo

33

& Goldfarb, 2008). It was observed that the water levels of the 1% KCIT solution
were slightly higher than the other dosage solutions when water bottles were
being changed out on a weekly basis. This could have been an indication that
mice under the higher dosages of KCIT may have not been drinking as much
water as mice on the lower dosages of KCIT or control water. These differences
in water levels were not significant and did not raise much of a concern.
However, we have taken into consideration that when a drug is administered
through a solution, we cannot account for the proper dosage the mice are
ingesting. In order to ensure the mice ingest the proper dosage in future
experiments, gavage or the usage of a supplemented diet will be taken into
consideration.
The treatments for cystinurics generally consist of the combinations of
high fluid intake, urine alkalinizing agents, and thiol drugs. Although thiol drugs
can significantly decrease stone formation and increase cystine solubility, there is
still a high risk of rapid stone reoccurrence in patients (Barbey et al., 2000; Chow
& Streem, 1996; Dolin et al., 2005; Khan et al., 2016). Thus, many patients are
required to have close surveillance from physicians such as frequent visits to the
clinic to perform radiological imaging and 24 hour urine collections. As a method
to target urine cystine solubility, KCIT is the standard of care for all cystinuric
patients. When LA is administered in the clinical setting, this new drug treatment
will be administered in combination with KCIT. Both KCIT and LA were
administered in conjunction to observe the possible adverse, additive, or
synergistic effects the two drugs have on one another. There are many questions
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that can arise in regards to why a high dosage of KCIT was paired with a medium
dosage of LA. A high dosage of KCIT was chosen for the combination
experiment due to our interest in mirroring clinical settings. For the clinical
setting, patients will be administered the highest tolerable dosage for their specific
body mass indexes. As discussed before, the 1% KCIT was discovered to be the
most tolerable dosage for our mice without any detrimental side effects through a
dosage experiment with the higher dosages of 1.5% KCIT, 2% KCIT, and 4%
KCIT. There are possibilities that this highest tolerable dosage of KCIT may be
masking the possible additive or synergistic effects of the administration of KCIT
and LA in conjunction. For future experiments, we shall consider administering a
lower dosage of KCIT.
For future directions, we plan to look into the mechanism of how LA
inhibits the rate of stone growth in our mice. In this particular study, we showed
that LA worked independently of alkalinizing urinary pH and the Nrf2 pathway to
inhibit stone growth and formation. Thus, the mechanism of LA to induce stone
inhibition and prevention is still unclear. We currently hypothesize LA to be
working through its metabolites to increase cystine solubility in the urine (Zee et
al., 2017).
In addition, there is an interest to start observing the effects of a LA
supplemented diet on other stone models aside from cystinuria and its effects on
stone growth and prevention. The stone model of interest will be the calcium
oxalate kidney stone model. This stone disease is the most commonly diagnosed
stone model with a prevalence of 80% of kidney stone cases (Goel & Wasserstein,
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2012; Khan et al., 2016). As discussed previously, KCIT is a standard of care for
cystinurics due to its observed ability to increase cystine solubility through the
means of increasing urinary pH. This alkalinizing agent is also a standard of care
for calcium stone formers because of citrate’s ability to bind to calcium and
reduce the amount of calcium that is available to bind with oxalate (Coe et al.,
2016; Khan et al., 2016). In our future studies, we plan to observe the effects and
efficiency of KCIT along with LA in the context of the calcium oxalate kidney
stone model just as we had previously done with the cystinuric kidney stone
model.
We will use the primary hypoxaluria type 1 disease model to observe
KCIT and LA’s effects on calcium oxalate stone formation. Primary hypoxaluria
is a genetic disorder characterized by the mutation of the alanine-glyoxylate
aminotransferase in the liver (Dutta et al., 2016). When this aminotransferase is
defected, oxalate is overproduced by the liver and is present in the kidney and
urine in abnormally high amounts. The high presence of oxalate leads to the
crystallization and eventually formation of calcium oxalate based kidney stones.
Although this disorder is hereditary, we want to use a model that will ensure the
formation of calcium oxalate stones. Methods such as the administration of
ethylene glycol to induce hyperoxaluria and hypercalciuria in mice may be
inefficient and may take months before the initial formation of calcium based
bladder stones. Thus, the primary hypoxaluria type 1 disease model will be our
calcium oxalate stone model of interest and we will observe the effects of KCIT
and LA on this type of stone formation.
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CONCLUSIONS

In summary, our results showed that TIO had a modest effect both on
stone growth inhibition and did not successfully prevent stone formation. In our
study, the varying effects on urinary pH and stone growth with KCIT were
consistent with what was seen in the clinical setting. We further confirm the
efficiency of LA as a stone growth inhibitor and stone preventor (Fig. 1 and Fig.
3). We hypothesized the Nrf2 pathway to be the mechanism in which LA worked
through in order ot inhibit the rate of stone growth. When LA was administered to
the Slc3a1-/- ; Nrf2 -/- mouse model, our results indicated that Nrf2 was not the
pathway LA worked through in order to inhibit stone growth.

When we pair up

KCIT with LA, there seemed to be no adverse effect on LA’s ability to inhibit the
rate of stone growth. This is an important observation for clinical settings when
both KCIT and LA will be administered in combination with one another. Our
research suggsted that LA is a new possible therapeutic for patients with
cystinuria since it has been shown to be an effective intervening and preventative
treatment.

37

REFERENCES

Arumuham, V., & Bycroft, J. (2016). The management of urolithiasis. Surgery,
34(7), 352–360. https://doi.org/10.1016/j.mpsur.2016.04.007
Asplin, D. M., & Asplin, J. R. (2013). The interaction of thiol drugs and urine pH
in the treatment of cystinuria. Journal of Urology, 189(6), 2147–2151.
https://doi.org/10.1016/j.juro.2012.12.031
Barbey, F., Joly, D., Rieu, P., Méjean, a, Daudon, M., & Jungers, P. (2000).
Medical treatment of cystinuria: critical reappraisal of long-term results. The
Journal of Urology, 163(5), 1419–23. https://doi.org/10.1016/S00225347(05)67633-1
Biyani, C. S., & Cartledge, J. J. (2006). Cystinuria-Diagnosis and Management.
EAU-EBU Update Series, 4(5), 175–183.
https://doi.org/10.1016/j.eeus.2006.06.001
Cebotaru, V., Kaul, S., Devuyst, O., Cai, H., Racusen, L., Guggino, W. B., &
Guggino, S. E. (2005). High citrate diet delays progression of renal
insufficiency in the ClC-5 knockout mouse model of Dent’s disease. Kidney
International, 68(2), 642–652. https://doi.org/10.1111/j.15231755.2005.00442.x
Chow, G. K., & Streem, S. B. (1996). Medical treatment of cystinuria: Results of
contemporary clinical practice. Journal of Urology, 156(5), 1576–1578.
https://doi.org/10.1016/S0022-5347(01)65451-X
Claes, D. J., & Jackson, E. (2012). Cystinuria: Mechanisms and management.

38

Pediatric Nephrology, 27(11), 2031–2038. https://doi.org/10.1007/s00467011-2092-6
Coe, F. L., Worcester, E. M., & Evan, A. P. (2016). Idiopathic hypercalciuria and
formation of calcium renal stones. Nature Reviews Nephrology, 12(9), 519–
533. https://doi.org/10.1038/nrneph.2016.101
Cohen, T. D., Streem, S. B., & Hall, P. (1995). Clinical Effect of Captopril on the
Formation and Growth of Cystine Calculi. The Journal of Urology, 154(1),
164–166. https://doi.org/10.1016/S0022-5347(01)67256-2
Crawhall, J. C., Scowen, E. F., & Watts, R. W. . (1963). Effect of Penicillamine
on Serum Iron. British Medical Journal, 588–590.
https://doi.org/10.1136/adc.40.214.651
Cui, W., Bai, Y., Miao, X., Luo, P., Chen, Q., Tan, Y., … Cai, L. (2012).
Prevention of diabetic nephropathy by sulforaphane: Possible role of Nrf2
upregulation and activation. Oxidative Medicine and Cellular Longevity,
2012. https://doi.org/10.1155/2012/821936
Dent, C. E., Friedman, M., Green, H., & Watson, L. C. A. (1965). Papers and
Originals Treatment of Cystinuria Cystinuria-Dent, (February).
Dolin, D. J., Asplin, J. R., Flagel, L., Grasso, M., & Goldfarb, D. S. (2005). Effect
of cystine-binding thiol drugs on urinary cystine capacity in patients with
cystinuria. Journal of Endourology / Endourological Society, 19(3), 429–32.
https://doi.org/10.1089/end.2005.19.429
Dutta, C., Avitahl-Curtis, N., Pursell, N., Larsson Cohen, M., Holmes, B.,
Diwanji, R., … Lai, C. (2016). Inhibition of Glycolate Oxidase With Dicer-

39

substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of
Primary Hyperoxaluria Type 1. Molecular Therapy, 24(4), 770–778.
https://doi.org/10.1038/mt.2016.4
Ercolani, M., Sahota, A., Schuler, C., Yang, M., Evan, A. P., Reimer, D., …
Levin, R. M. (2010). Bladder outlet obstruction in male cystinuria mice.
International Urology and Nephrology, 42(1), 57–63.
https://doi.org/10.1007/s11255-009-9597-y
Goel, R., & Wasserstein, A. G. (2012). Diagnostic and Treatment Strategies.
Consultant, (Febuary), 227. Retrieved from
http://www.ncbi.nlm.nih.gov/books/NBK7461/
Halperin, E. C., Thier, S. O., & Rosenberg, L. E. (1981). The use of Dpenicillamine in cystinuria: Efficacy and untoward reactions. Yale Journal of
Biology and Medicine, 54(6), 439–446.
Joly, D., Rieu, P., Mejean, A., Gagnadoux, M.-F., Daudon, M., & Jungers, P.
(1999). Treatment of cystinuria. Practical Pediatric Nephrology, 13(March),
945–950. https://doi.org/10.1136/bmj.1.5396.1507-c
Khan, S. R., Pearle, M. S., Robertson, W. G., Gambaro, G., Canales, B. K., Doizi,
S., … Tiselius, H.-G. (2016). Kidney stones. Nature Reviews Disease
Primers, 16008. https://doi.org/10.1038/nrdp.2016.8
Krieger, N. S., Asplin, J. R., Frick, K. K., Granja, I., Culberston, C. D., Ng, A., …
Bushinsky, D. A. (2015). Re: Effect of Potassium Citrate on Calcium
Phosphate Stones in a Model of Hypercalciuria. Journal of Urology, 194(5),
1506. https://doi.org/10.1016/j.juro.2015.08.022

40

Lewandowski, S., & Rodgers, A. L. (2004). Idiopathic calcium oxalate
urolithiasis: Risk factors and conservative treatment. Clinica Chimica Acta,
345(1–2), 17–34. https://doi.org/10.1016/j.cccn.2004.03.009
Lii, C., Liu, K., Cheng, Y., Lin, A., Chen, H., & Tsai, C. (2010). Sulforaphane
and a -Lipoic Acid Upregulate the Expression of the π Class of Glutathione S
-Transferase through c-Jun and. Journal of Nutrition, 885–892.
https://doi.org/10.3945/jn.110.121418.885
Mattoo, A., & Goldfarb, D. S. (2008). Cystinuria. Seminars in Nephrology, 28(2),
181–191. https://doi.org/10.1016/j.semnephrol.2008.01.011
Scales, C. D., Smith, A. C., Hanley, J. M., & Saigal, C. S. (2012). Prevalence of
kidney stones in the United States. European Urology, 62(1), 160–165.
https://doi.org/10.1016/j.eururo.2012.03.052
Sloand, J. a, & Izzo, J. L. (1987). Captopril reduces urinary cystine excretion in
cystinuria. Archives of Internal Medicine, 147(8), 1409–12.
https://doi.org/10.1001/archinte.1987.00370080045011
Turner, P. V, Brabb, T., Pekow, C., & Vasbinder, M. a. (2011). Administration of
substances to laboratory animals: routes of administration and factors to
consider. J Am Assoc Lab Anim Sci, 50(5), 600–613. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/22330705
Worcester, E. M., & Coe, F. L. (2008). New Insights into the Pathogenesis of
Idiopathic Hypercalciuria. Semin Nephrol, 144(5), 724–732.
https://doi.org/10.1038/jid.2014.371
Zee, T., Bose, N., Zee, J., Beck, J. N., Yang, S., Parihar, J., … Kapahi, P. (2017).

41

alpha-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of
cystinuria. Nature Medicine.

42

